PharmaVentures Client QRx Pharma Announces Strategic Partnership with Actavis

Agreement for US sales of MoxDuo® IR to address the $2.5 billion acute pain market in 2012 
 
Sydney, Australia and Bedminster, New Jersey – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a binding Letter of Intent (LOI) with Actavis Inc. for the formation of a strategic partnership to commercialise MoxDuo IR in the US acute pain marketplace. 
 

PharmaVentures Client Vital Foods Announces Partnership with Nestle Health Science

Mon 18 Jul 2011 : Vital Foods partners with Nestlé Health Science

Vital Foods today announced that Nestlé Health Science has become a strategic investor and taken a minority stake in the company. The terms of the transaction are not being disclosed.

PharmaVenture Client Bergen Bio Licenses R428

PharmaVentures Client BergenBio entered into an agreement for Rigel's preclinical candidate, R428 (now referred to as BGB324), an Axl kinase inhibitor for oncology.

PharmaVentures facilitates manufacturing divestment for UCB to Aesica Pharmaceuticals

Oxford, UK. 01 March 2011 - PharmaVentures Ltd acted as exclusive advisor and broker to the global biopharma company, UCB in its successful strategic partnership with UK-based developer and manufacturer Aesica Pharmaceuticals.

PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.

Oxford, UK, 26th October, 2010: PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy’s Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy’s exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics’ leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

PharmaVentures acts as exclusive advisor to sanofi-aventis in landmark divestment deal with Covance

Oxford, UK. 01 October 2010 - PharmaVentures are pleased to announce that they acted as transaction advisors and sale process executioners for sanofi-aventis in their strategic deal with Covance. Under the terms of the agreement, sanofi-aventis will retain access to some of the capabilities which have been divested to Covance as part of a long-term strategic alliance. Covance will provide sanofi-aventis with a 10-year sole source relationship for central lab services.

Pages

 

_

PharmaVentures InSights